eGenesis
Share
08/23/2022
Organ transplant is the most effective solution to organ failure – but supply remains an issue. Our CEO, Mike Curtis, Ph.D., explained to Genetic Engineering & Biotechnology News how eGenesis has generated organs that have achieved long-term transplant survival in preclinical studies.
bit.ly/3SyFoyx
06/07/2022
Our CEO, Mike Curtis, Ph.D., will be speaking on the upcoming Financial Times panel on June 9th at 11am EDT to highlight xenotransplantation as a new frontier of healthcare innovation.
To register: https://bit.ly/3mb4qoa
We are honored to sponsor the 2022 National Kidney Foundation Workshop in Washington DC. This event has brought together leaders in the field of to discuss the latest innovation in the development of xenografts for the treatment of patients with organ failure and the path ahead in advancing products to the clinic.
Today we recognize all the hard-working doctors, especially those physicians on our Board of Directors and Advisory Boards, who are helping us advance our human compatible organs and cells towards patients in need of a transplant.
Tomorrow, our President of Research and Development, Mike Curtis, Ph.D., is participating in a Xenotransplantation Innovation Day hosted by CareDx, Inc. He will cover the “Development of Human Compatible (HuCo) Organs and Cells with the EGEN Platform.”
To view, register here: https://bit.ly/3tYs7DO
Click here to claim your Sponsored Listing.
Category
Contact the business
Website
Address
Cambridge, MA
02139
